Drug
Ziftomenib clinical trials
Also written KO-539.
- studies test it
- 13
- open now
- 12
- in phase 3
- 1
- first study started
- 2023
Keep track of what changes. Save the ziftomenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Studies by the year they started
13 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 3
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 9
M.D. Anderson Cancer Center (4) · Kura Oncology, Inc. (3) · Massachusetts General Hospital (2) · PedAL BCU, LLC (1) · Uma Borate (1) · Tanja Andrea Gruber (1) · Kyowa Kirin Co., Ltd. (1)
Often tested with
Tested in the same studies.
Venetoclax (3) · Azacitidine (2) · Olutasidenib (1) · Daunorubicin (1) · Cytarabine (1) · Mezigdomide (1) · Quizartinib (1) · Gemtuzumab (1)
Studies
Open first, then newest update. How each study uses ziftomenib is read from its arms, and is right about nine times in ten.
Testing it · 13
- Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLRecruitingPhase 3Kura Oncology, Inc.NCT07007312Written as Ziftomenib
- Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute LeukemiaRecruitingPhase 1PedAL BCU, LLCNCT06376162Written as Ziftomenib
- Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLRecruitingPhase 1Massachusetts General HospitalNCT07355335Written as Ziftomenib
- Ziftomenib Maintenance Post Allo-HCTRecruitingPhase 1Massachusetts General HospitalNCT06440135Written as Ziftomenib
- Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06769490Written as Ziftomenib
- A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute LeukemiasRecruitingPhase 1M.D. Anderson Cancer CenterNCT06397027Written as Ziftomenib
- Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyRecruitingPhase 2Uma BorateNCT06930352Written as Ziftomenib
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1Kura Oncology, Inc.NCT06001788Written as Ziftomenib
- A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 1M.D. Anderson Cancer CenterNCT06448013Written as Ziftomenib
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingPhase 1/2Tanja Andrea GruberNCT05848687Written as Ziftomenib
- A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid LeukemiaRecruitingPhase 2Kyowa Kirin Co., Ltd.NCT07623616Written as ziftomenib
- A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingPhase 1Kura Oncology, Inc.NCT06655246Written as ziftomenib
- Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid LeukemiaActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT07411586Written as Ziftomenib
Given in every arm · 2 — ziftomenib is usual care beside what is tested
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLRecruitingPhase 1Kura Oncology, Inc.NCT05735184Written as Ziftomenib
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid LeukemiaActive, not recruitingPhase 1/2Kura Oncology, Inc.NCT04067336Written as Ziftomenib
Codes
What other systems call ziftomenib · ClinicalTrials.gg INT002179
- MeSH (NLM) C000731960ziftomenibOne source NLM
- UNII (FDA) 4MOD1F4ENCZIFTOMENIBConfirmed FDA, NLM, Wikidata
- Wikidata Q133521494ziftomenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C164227ZiftomenibOne source FDA
- DrugBank DB17171One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731960 | ziftomenib | One source NLM |
| UNII (FDA) | 4MOD1F4ENC | ZIFTOMENIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q133521494 | ziftomenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C164227 | Ziftomenib | One source FDA |
| DrugBank | DB17171 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.